{"id":"W2202588822","doi":"10.1159/000381589","title":"A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium","year":2015,"lang":"en","type":"article","venue":"Urologia Internationalis","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"Steinbach Bible College","funders":"AstraZeneca","keywords":"Medicine; Gefitinib; Gemcitabine; Chemotherapy; Internal medicine; Oncology; Concomitant; Tolerability; Phases of clinical research; Nausea; Epidermal growth factor receptor; Clinical endpoint; Adverse effect; Cancer; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009540202,0.0002256185,0.0006785477,0.0001075354,0.00006504955,0.000008804478,0.0006809924,0.00003166379,0.0000570069],"category_scores_gemma":[0.0001419542,0.000101922,0.00005281296,0.0005721449,0.0004407459,0.0001623054,0.0002388836,0.0002545263,1.534771e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001207818,"about_ca_system_score_gemma":0.0007424735,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004069056,"about_ca_topic_score_gemma":0.003514775,"domain_scores_codex":[0.9960707,0.0008145793,0.0009472943,0.000397868,0.001521408,0.0002481823],"domain_scores_gemma":[0.9973228,0.0002101491,0.0007196125,0.0005270045,0.00113428,0.00008618394],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3572358,0.103113,0.4770439,0.000329401,0.001559661,0.00005339824,0.05513796,0.001035957,0.003599285,0.0000396149,0.0001545914,0.0006975033],"study_design_scores_gemma":[0.3552001,0.1568727,0.463066,0.0003407546,0.0008519631,0.00001360752,0.01412659,0.001671741,0.007618083,0.00001553009,0.00002282598,0.0002000349],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939152,0.00001854805,0.00001976408,0.0001391613,0.00007050234,0.004113187,0.001497121,0.000005083453,0.0002214387],"genre_scores_gemma":[0.9988171,0.000002530277,0.0007264575,0.00006059291,0.00002184711,0.00008185999,0.0000600413,0.0000351111,0.0001944074],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05375975,"threshold_uncertainty_score":0.6151223,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1165180056392242,"score_gpt":0.3822319459424833,"score_spread":0.2657139403032591,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}